Ronnie Shapira-Frommer, MD, on the Rationale for the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

Video

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about data focusing on a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.

CancerNetwork® sat down with Ronnie Shapira-Frommer, MD, to discuss the rationale for the phase 2 KEYNOTE-158 trial (NCT02628067), which examined pembrolizumab (Keytruda) monotherapy in patients with advanced solid tumors.

At the Society of Gynecological Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer, Shapira-Frommer presented data on a cohort of patients with vulvar cancer treated on the trial. Results showed that patients with previously treated vulvar squamous cell carcinoma who received single-agent pembrolizumab experienced durable responses across PD-L1 expression levels.

Transcription:

The KEYNOTE-158 study was a multicohort, phase 2 study in [multiple tumor types], and vulvar cancer is one of them. Endometrial cancer, cervical cancer, mesothelioma, and other cohorts were included in the study. Vulvar cancer is a rare cancer, it’s very difficult to enroll patients. Usually, they are elderly patients with multiple diseases [aside from cancer]. It’s also quite hard to evaluate disease since it’s pelvic disease [with] local spreading of disease.

Vulvar cancer was one of the cohorts of the study, and it’s also important to know that vulvar cancer, in most cases, is related to HPV [human papillomavirus] infection. As we know in cervical cancer, the role of pembrolizumab was proven in another cohort of the KEYNOTE-158 study, and it was this study led to the approval by the FDA for this cohort of patients with cervical cancer [that is] PD-L1 positive. Therefore, vulvar cancer was included as well.

References

Frommer RS, Mileshkin L, Manzyuk L, et al. Pembrolizumab for Vulvar Squamous Cell Carcinoma: Results From the Phase 2 KEYNOTE-158 Study. Abstract presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer; March 19-21, 2021; Virtual. Abstract 11603.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content